@article{AvotaBodemChithelenetal.2021, author = {Avota, Elita and Bodem, Jochen and Chithelen, Janice and Mandasari, Putri and Beyersdorf, Niklas and Schneider-Schaulies, J{\"u}rgen}, title = {The Manifold Roles of Sphingolipids in Viral Infections}, series = {Frontiers in Physiology}, volume = {12}, journal = {Frontiers in Physiology}, issn = {1664-042X}, doi = {10.3389/fphys.2021.715527}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-246975}, year = {2021}, abstract = {Sphingolipids are essential components of eukaryotic cells. In this review, we want to exemplarily illustrate what is known about the interactions of sphingolipids with various viruses at different steps of their replication cycles. This includes structural interactions during entry at the plasma membrane or endosomal membranes, early interactions leading to sphingolipid-mediated signal transduction, interactions with internal membranes and lipids during replication, and interactions during virus assembly and budding. Targeted interventions in sphingolipid metabolism - as far as they can be tolerated by cells and organisms - may open novel possibilities to support antiviral therapies. Human immunodeficiency virus type 1 (HIV-1) infections have intensively been studied, but for other viral infections, such as influenza A virus (IAV), measles virus (MV), hepatitis C virus (HCV), dengue virus, Ebola virus, and severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), investigations are still in their beginnings. As many inhibitors of sphingolipid metabolism are already in clinical use against other diseases, repurposing studies for applications in some viral infections appear to be a promising approach.}, language = {en} } @phdthesis{Chithelen2022, author = {Chithelen, Janice}, title = {Targeting viral and host factors to optimize anti-measles virus therapy}, doi = {10.25972/OPUS-29305}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-293059}, school = {Universit{\"a}t W{\"u}rzburg}, year = {2022}, abstract = {Measles is an ancient disease with historical records as early as the 9th century. Extensive study as well as advances in scientific knowledge of virology have led to identification of the viral pathogen and subsequent development of an effective vaccine leading to global efforts towards measles elimination. In 2018, around 140,000 deaths were reported due to measles with incomplete vaccine coverage being one of the leading causes of resurgence. Measles is highly contagious and often regarded as a childhood illness. However, measles is associated with a number of complications and persistent infections like subacute sclerosing panencephalitis (SSPE), which have brought into focus the need for specific anti-viral therapies. The aim of this study was to target host and viral factors to optimize anti-measles virus therapy. Our approach was to test a panel of compounds known to inhibit host cell functions or viral factors for their antiviral effect on measles replication. Primary human lymphocytes, persistently infected NT2 cells and post-mitotic neurons were used as in vitro model systems of acute, persistent and neuronal infection respectively to test the inhibitors. Using the inhibitors Ceranib-2 and SKI-II to target the sphingolipid metabolism enzymes acid ceramidase and sphingosine kinase in infected human primary lymphocytes, we observed a decreased protein translational capacity mediated by mTORC1, EIF4E and ribosomal protein S6 phosphorylation that probably contributes to the antiviral effect. In the persistently infected neural NT2 cells and post-mitotic neurons derived from LUHMES cells, we observed effective infection inhibition and viral clearance upon treatment with a small non-nucleoside inhibitor (ERDRP-0519) specifically targeting the Morbillivirus large polymerase. Other inhibitors such as Ribavirin and Favipiravir were less effective. To conclude, 1) we identified a mTOR associated protein translation axis associated with the sphingolipid metabolism, which affects measles virus replication and 2) In vitro persistently infected neuronal and post-mitotic neuron models were successfully used as a rapid method to test antivirals against measles virus.}, language = {en} } @article{ChithelenFrankeLaenderetal.2022, author = {Chithelen, Janice and Franke, Hannah and L{\"a}nder, Nora and Grafen, Anika and Schneider-Schaulies, J{\"u}rgen}, title = {The sphingolipid inhibitors ceranib-2 and SKI-II reduce measles virus replication in primary human lymphocytes: effects on mTORC1 downstream signaling}, series = {Frontiers in Physiology}, volume = {13}, journal = {Frontiers in Physiology}, issn = {1664-042X}, doi = {10.3389/fphys.2022.856143}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-265988}, year = {2022}, abstract = {The bioactive sphingolipids ceramide and sphingosine-1-phosphate (S1P) are involved in the regulation of cell homeostasis and activity ranging from apoptosis to proliferation. We recently described that the two compounds ceranib-2 (inhibiting acid ceramidase) and SKI-II [inhibiting the sphingosine kinases 1 and - 2 (SphK1/2)] reduce mTORC1 activity and measles virus (MV) replication in human primary peripheral blood lymphocytes (PBL) by about one log step. We now further investigated whether mTORC1 downstream signaling and viral protein expression may be affected by ceranib-2 and/or SKI-II. Western blot analyses showed that in uninfected cells the phosphorylation of the eukaryotic initiation factor 4E (eIF4E) was reduced by both inhibitors. Interestingly, MV infection led to an increase of rpS6 protein levels and phosphorylation of eIF4E. Treatment with both inhibitors reduced the rpS6 protein expression, and in addition, SKI-II reduced rpS6 phosphorylation. The phosphorylation of eIF4E was slightly reduced by both inhibitors. In addition, SKI-II led to reduced levels of IKK in MV-infected cells. Both inhibitors reduced the expression of viral proteins and the titers of newly synthesized MV by approximately one log step. As expected, SKI-II and rapamycin reduced also the virally encoded GFP expression; however, ceranib-2 astonishingly led to increased levels of GFP fluorescence. Our findings suggest that the inhibitors ceranib-2 and SKI-II act via differential mechanisms on MV replication. The observed effects on mTORC1 downstream signaling, predominantly the reduction of rpS6 levels by both inhibitors, may affect the translational capacity of the cells and contribute to the antiviral effect in human primary PBL.}, language = {en} } @article{GrafenSchumacherChithelenetal.2019, author = {Grafen, Anika and Schumacher, Fabian and Chithelen, Janice and Kleuser, Burkhard and Beyersdorf, Niklas and Schneider-Schaulies, J{\"u}rgen}, title = {Use of acid ceramidase and sphingosine kinase inhibitors as antiviral compounds against measles virus infection of lymphocytes in vitro}, series = {Frontiers in Cell and Developmental Biology}, volume = {7}, journal = {Frontiers in Cell and Developmental Biology}, number = {218}, issn = {2296-634X}, doi = {10.3389/fcell.2019.00218}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-196099}, year = {2019}, abstract = {As structural membrane components and signaling effector molecules sphingolipids influence a plethora of host cell functions, and by doing so also the replication of viruses. Investigating the effects of various inhibitors of sphingolipid metabolism in primary human peripheral blood lymphocytes (PBL) and the human B cell line BJAB we found that not only the sphingosine kinase (SphK) inhibitor SKI-II, but also the acid ceramidase inhibitor ceranib-2 efficiently inhibited measles virus (MV) replication. Virus uptake into the target cells was not grossly altered by the two inhibitors, while titers of newly synthesized MV were reduced by approximately 1 log (90\%) in PBL and 70-80\% in BJAB cells. Lipidomic analyses revealed that in PBL SKI-II led to increased ceramide levels, whereas in BJAB cells ceranib-2 increased ceramides. SKI-II treatment decreased sphingosine-1-phosphate (S1P) levels in PBL and BJAB cells. Furthermore, we found that MV infection of lymphocytes induced a transient (0.5-6 h) increase in S1P, which was prevented by SKI-II. Investigating the effect of the inhibitors on the metabolic (mTORC1) activity we found that ceranib-2 reduced the phosphorylation of p70 S6K in PBL, and that both inhibitors, ceranib-2 and SKI-II, reduced the phosphorylation of p70 S6K in BJAB cells. As mTORC1 activity is required for efficient MV replication, this effect of the inhibitors is one possible antiviral mechanism. In addition, reduced intracellular S1P levels affect a number of signaling pathways and functions including Hsp90 activity, which was reported to be required for MV replication. Accordingly, we found that pharmacological inhibition of Hsp90 with the inhibitor 17-AAG strongly impaired MV replication in primary PBL. Thus, our data suggest that treatment of lymphocytes with both, acid ceramidase and SphK inhibitors, impair MV replication by affecting a number of cellular activities including mTORC1 and Hsp90, which alter the metabolic state of the cells causing a hostile environment for the virus.}, language = {en} }